Orlando, FL -- (SBWIRE) -- 10/10/2013 -- Hot Stock Profits provides investors and traders with valuable trading tools and content as well as micro-cap stock alerts via eMail and text messages. To Join Our Text Message Alerts Service Just Text The Word Stocks To 555888 From Your Cell Phone. Our Focus Today Is On Pacific Biosciences of California (NASDAQ:PACB), Optimer Pharmaceuticals, Inc. (NASDAQ:OPTR).
Pacific Biosciences of California (NASDAQ:PACB) shares jumped 0.20% to $4.93. The company will hold its quarterly conference call to discuss its Third Quarter 2013 financial results on Tuesday, October 22, 2013, at 4:30pm Eastern Time.
Additionally, On September 25, 2013, Pacific BioSciences announced that it has entered into an agreement with Roche Diagnostics for developing diagnostic products, based on the Company's Single Molecule, Real-Time (SMRT(R)) technology. Pacific Biosciences will develop and manufacture certain products intended for clinical use, which it will sell exclusively to Roche.
Are investors worried about the recent updates with PACB? Find out with a free trend analysis HERE
Optimer Pharmaceuticals, Inc. (NASDAQ:OPTR) shares declined 0.24% to $12.54. Zacks reaffirmed their neutral rating on shares of Optimer in a research note issued to investors on Oct. 1. The firm currently has a $13.00 price target on the stock. The company is a biopharmaceutical company focused on developing and commercializing hospital specialty products. . The Company’s development is focused on products that treat gastrointestinal infections and related diseases. Its two products OPT-822/821 and CEM-101 (OP-1068) are in clinical development.
Is OPTR going to continue its rally or drop like a rock? Find out with a free trend analysis HERE
Join Our Mobile SMS Alerts By Texting Stocks To 555888
HotStockProfits.com continuously monitors and scans the markets for day trading and swing trading signals on NASDAQ, NYSE, AMEX, OTCBB and Pink Sheet companies for its free e-newsletter subscribers.
HotStockProfits.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit HotStockProfits.com website, for complete risks and disclosures.
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)